Impetigo clinical trials
The registry lists 30 studies for Impetigo across more than 10 countries. 3 are recruiting or about to start. 17 of them are mainly about Impetigo (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-07.
Get an email when these change. Save the Impetigo studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
GlaxoSmithKline (5) · LEO Pharma (3) · NovaBay Pharmaceuticals, Inc. (2) · Lytix Biopharma AS (2) · Ferrer Internacional S.A. (2) · Centro Studi Gised (1) · UNION therapeutics (1) · Royal North Shore Hospital (1)
What is being tested here
Drugs under test in Impetigo studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Ozenoxacin | 0 | 2 | 2 |
| Ltx-109 | 0 | 0 | 2 |
| Mupirocin | 0 | 1 | 1 |
| Idarubicin | 0 | 0 | 1 |
| Ivermectin | 0 | 0 | 1 |
| Azithromycin | 0 | 0 | 1 |
| ATX201 | 0 | 0 | 1 |
| Retapamulin | 0 | 0 | 1 |
| NVC-422 | 0 | 0 | 1 |
| Fusidic Acid | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
- Nov 2026Perspectives on Antibiotics and Tracking Symptoms in Children · Murdoch Childrens Research Institute
- Mar 2027Secondary Bacterial Infections and Nasal Colonization in Scabies and Atopic Dermatitis · Istanbul Medeniyet University
Who these studies take
Of the 1 Impetigo studies recruiting now, 0 (0%) set no upper age limit and 1 (100%) stop at 75 or younger. 1 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (100%) | 1 (100%) |
| 18 | 0 (0%) | 0 (0%) |
| 30 | 0 (0%) | 0 (0%) |
| 40 | 0 (0%) | 0 (0%) |
| 50 | 0 (0%) | 0 (0%) |
| 65 | 0 (0%) | 0 (0%) |
| 75 | 0 (0%) | 0 (0%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 30 studies, recruiting or not: 37% stop at 75 or younger and 33% at 65; 87% take children; 0% are for women only and 0% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 30 of 30. search them.
- Perspectives on Antibiotics and Tracking Symptoms in ChildrenRecruitingNCT07093749Not applicable1 country
- Secondary Bacterial Infections and Nasal Colonization in Scabies and Atopic DermatitisNot yet recruitingNCT078136111 country
- Comparative Study of Adherence to Antibiotic Therapy Among Pediatric Patients: Hospital Emergency Department vs. Primary Care CenterNot yet recruitingNCT07711756
- Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and DermatologistsCompletedNCT074289151 country
- Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary CareCompletedNCT05226260Not applicable1 country
- The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or ImpetigoCompletedNCT00758862Phase 21 country
- Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)CompletedNCT00626795Phase 22 countries
- Fucidin® Cream in the Treatment of ImpetigoTerminatedNCT00986856Phase 42 countries
- Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With ImpetigoCompletedNCT02090764Phase 31 country
- Safety and Efficacy of Mupirocin Gel in Children With ImpetigoCompletedNCT04287777Phase 31 country
- Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in FijiCompletedNCT03177993Not applicable1 country
- Azithromycin - Ivermectin Mass Drug Administration for Skin DiseaseCompletedNCT02775617Phase 41 country
- Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of BergamoCompletedNCT02902822Not applicable1 country
- Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With ImpetigoCompletedNCT03429595Phase 21 country
- Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSACompletedNCT00852540Phase 31 country
- Topical SB-275833 Ointment, 1% For The Treatment Of ImpetigoCompletedNCT00133874Phase 310 countries
- Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.CompletedNCT00555061Phase 49 countries
- Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo OintmentCompletedNCT00133848Phase 35 countries
- Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With ImpetigoCompletedNCT01397461Phase 32 countries
- Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue InfectionCompletedNCT01126268Phase 41 country
- ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)CompletedNCT014456001 country
- Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in ImpetigoCompletedNCT01670032Phase 2/32 countries
- A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in ImpetigoCompletedNCT01803035Phase 21 country
- The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical TrialStatus unknownNCT01943136Phase 11 country
- Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo PatientsCompletedNCT01171326Phase 21 country
- EU PV for Retapamulin-PrescribingCompletedNCT01153828
- Citriodiol® and ImpetigoStatus unknownNCT01611909Phase 2/31 country
- Safety and Efficacy of Topical NVC-422 Gel in ImpetigoCompletedNCT01367314Phase 21 country
- A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin InfectionCompletedNCT01223222Phase 21 country
- Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern TerritoryCompletedNCT008847281 country